Janney Capital Management LLC Reduces Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Janney Capital Management LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 1.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 17,898 shares of the pharmaceutical company’s stock after selling 192 shares during the period. Janney Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $7,283,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of VRTX. Janney Montgomery Scott LLC grew its holdings in shares of Vertex Pharmaceuticals by 5.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 128,370 shares of the pharmaceutical company’s stock valued at $52,232,000 after buying an additional 7,176 shares during the last quarter. First Turn Management LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter valued at about $33,236,000. Fagan Associates Inc. increased its holdings in shares of Vertex Pharmaceuticals by 1.4% in the fourth quarter. Fagan Associates Inc. now owns 25,442 shares of the pharmaceutical company’s stock valued at $10,352,000 after purchasing an additional 355 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Vertex Pharmaceuticals by 8.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 275,415 shares of the pharmaceutical company’s stock worth $113,116,000 after purchasing an additional 21,332 shares during the last quarter. Finally, Westpac Banking Corp lifted its holdings in shares of Vertex Pharmaceuticals by 2.4% during the fourth quarter. Westpac Banking Corp now owns 3,556 shares of the pharmaceutical company’s stock worth $1,447,000 after purchasing an additional 83 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Barclays boosted their price objective on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $432.18.

Read Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded up $8.90 during trading on Wednesday, reaching $437.49. The stock had a trading volume of 1,059,223 shares, compared to its average volume of 1,218,891. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40. The stock has a market cap of $112.89 billion, a PE ratio of 28.31, a PEG ratio of 2.05 and a beta of 0.39. The business has a fifty day moving average price of $408.01 and a 200-day moving average price of $402.88.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.67 earnings per share. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.